Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 217

Sort by

Sort Order Select

Journal Articles

Targeting Enterobacter cloacae attenuates osteolysis by reducing ammonium in multiple myeloma

Blood (2025) 145 (17): 1876–1889.

https://doi.org/10.1182/blood.2024025694

Published: 2025

Includes: Supplemental data

Journal Articles

Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE

Blood (2024) 144 (26): 2706–2717.

https://doi.org/10.1182/blood.2024024667

Published: 2024

Includes: Supplemental data

Journal Articles

A Phase I First-in-Human, Open-Label Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0500, a Humanized GPRC5D-BCMA-CD3 Trispecific Antibody, in Participants with Relapsed or Refractory Multiple Myeloma

Yan Xu, Zhen Cai, Zhongjun Xia, Chen Yang, Jia Chen, Zewen Zhu, Xiaojuan Jing, Ji Tian, Nating Zhang, Ailing Cui, Jianxing Tang, Haolin Sun, Lugui Qiu

Blood (2024) 144 (Supplement 1): 3381.2.

https://doi.org/10.1182/blood-2024-200737

Published: 2024

Journal Articles

MYD88 Mutations in Chronic Lymphocytic Leukemia Exhibit Distinct Biological Behaviors and Prognostic Implications

Yuting Yan, Yulan Zhou, Weihao Chen, Jun Wang, Tingyu Wang, Ying Yu, Yujiao Jia, Zhen Yu, Lugui Qiu, Fei Li, Shuhua Yi

Blood (2024) 144 (Supplement 1): 4624.

https://doi.org/10.1182/blood-2024-207323

Published: 2024

Journal Articles

Spruce-TN CLL/SLL (cwCLL-002 study): An Ongoing Study of MRD-Guided Sonrotoclax Plus Zanubrutinib in Treatment-Naïve Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)

Shuhua Yi, Tingyu Wang, Fei Li, Jingdong Zhang, Xingli Zou, Yanping Ma, Lugui Qiu

Blood (2024) 144 (Supplement 1): 1875.1.

https://doi.org/10.1182/blood-2024-201175

Published: 2024

Journal Articles

Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial

Elena Zamagni, Tobias Silzle, Ivan Špička, Sabrin Tahri, Sarah Lonergan, Inger S. Nijhof, Antonietta Pia Falcone, Evangelos Terpos, Jakub Radocha, Roberto Mina, Guldane Cengiz Seval, Meral Beksac, Cesar Rodriguez, Marcelo C. Pasquini, Michel Delforge, Vania Hungria, Donna Reece, Philippe Moreau, Yael C. Cohen, Kihyun Kim, Dominik Dytfeld, Jiří Minařík, Irene Strassl, Jelena Bila, Martin Schreder, Janusz Krawczyk, Fredrik Schjesvold, Caroline Cicin-Sain, Christoph Driessen, Gordon Cook, Lugui Qiu, Gonzalo Martin Garate, Agoston Gyula Szabo, Roman Hájek, Marc S. Raab, Silvia Mangiacavalli, Hermann Einsele, Andrew Spencer, Mario Boccadoro, Helen Vassalou, Lixia Pei, Yingqi Shi, Maria Krevvata, Ryan Gruber, Caline Sakabedoyan, Margaret Cobb, Jagoda Jasielec, Himal Amin, Rachel Kobos, Pieter Sonneveld, Niels W.C.J. van de Donk

Blood (2024) 144 (Supplement 1): 494.

https://doi.org/10.1182/blood-2024-205608

Published: 2024

Journal Articles

Single-Cell RNA Analysis of Bone Marrow Mononuclear Cells Reveals Abnormal Activation of T Cells and Monocytes, and Identifies CD35 As a Novel Biomarker and Therapeutic Target in Waldenstrom Macroglobulinemia

Hao Sun, Xia Liu, Maria Luisa Guerrera, Nickolas Tsakmaklis, Amanda Kofides, Andres Felipe Ramirez Gamero, Catherine A. Flynn, Christopher J Patterson, Mu Hao, Lugui Qiu, Shayna R Sarosiek, Jorge J. Castillo, Zachary R Hunter, Shirong Liu, Steven P. Treon

Blood (2024) 144 (Supplement 1): 743.

https://doi.org/10.1182/blood-2024-211488

Published: 2024

Journal Articles

Dissecting the Interplay between Primary Central Nervous System Lymphoma Cells and the Microenvironment Using Single-Cell Transcriptomic Analysis

Qianru Zhang, Wenqiang Yan, Lu Sun, Guoqing Han, Qiaoli Wu, Yiran Cui, Bolin Liu, Feng Zhang, Ke Pu, Mingchao Zhang, Xiaobing Zhang, Lugui Qiu, Qingguo Li, Gang An, Yuxuan Liu

Blood (2024) 144 (Supplement 1): 1590.

https://doi.org/10.1182/blood-2024-202680

Published: 2024

Journal Articles

Acalabrutinib Versus Chlorambucil Plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia: A Randomized, Multicenter, Open-Label, Phase 3 Study

Lugui Qiu, Zhuogang Liu, Shuhua Yi, Thanh Nguyen, Wen-Juan Yu, Keshu Zhou, Haiwen Huang, Udomsak Bunworasate, Man Huynh, Hui Zhou, Su-Peng Yeh, Yiqiu Wang, Xiaofeng Liu, Wei Fu

Blood (2024) 144 (Supplement 1): 3251.

https://doi.org/10.1182/blood-2024-193476

Published: 2024

Journal Articles

26S Proteasome Non-Atpase Subunit 3 (PSMD3/Rpn3) Is a Potential Therapeutic Target in Multiple Myeloma

Teng Fang, Yan Song, Ting Du, Arghya Ray, Xueping Wan, Minxing Wang, Sindhu C Pillai, Md. Abu Musa, Mu Hao, Lugui Qiu, Dharminder Chauhan, Kenneth C. Anderson

Blood (2024) 144 (Supplement 1): 1905.

https://doi.org/10.1182/blood-2024-206000

Published: 2024

Journal Articles

Response-Driven Dose-Intensified Immunochemotherapy ± Autologous Stem Cell Transplantation in Previously Untreated Patients with High-Risk Aggressive B-Cell Lymphoma: Results of the DLCL002 Phase 2 Trial

Ting Xie, Wei Liu, Wenyang Huang, Huimin Liu, Weiwei Sui, Yi Wang, Wenjie Xiong, Yan Xu, Lugui Qiu, Dehui Zou

Blood (2024) 144 (Supplement 1): 4481.

https://doi.org/10.1182/blood-2024-204363

Published: 2024

Journal Articles

TRIM28 Serves As a Key Regulator of Protein Homeostasis and Mediates Proteasome Inhibitor Resistance in Multiple Myeloma

Teng Fang, Lanting Liu, Hao Sun, Xiyue Sun, Zhen Yu, Lugui Qiu, Mu Hao

Blood (2024) 144 (Supplement 1): 4668.

https://doi.org/10.1182/blood-2024-204159

Published: 2024

Journal Articles

EX103, a Newly Re-Designed CD20×CD3 Molecule, Induces High Response in Heavily Pretreated Relapsed/Refractory (R/R) Patients with B-Cell Non-Hodgkin Lymphoma (B-NHL)

Mingyuan Sun, Lugui Qiu, Keshu Zhou, Kai Hu, Chunkang Chang, Dong Wu, Zhenling Li, Ming Gong, Wenjun Zhang, Daniel Yang, Jiali Lu, Junyuan Qi

Blood (2024) 144 (Supplement 1): 3103.

https://doi.org/10.1182/blood-2024-193606

Published: 2024

Journal Articles

Classification of NK-Large Granular Lymphocytic Leukemia By CD56 Expression

Blood (2024) 144 (Supplement 1): 4439.

https://doi.org/10.1182/blood-2024-201476

Published: 2024

Journal Articles

Promising Safety and Efficacy of Eque-Cel Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients: Primary Real World Data from a Single Center

Yan Xu, Gang An, Wei LIU, Qi Wang, Yi Wang, Shuaishuai Zhang, Wenjie Xiong, Tengteng Yu, Mingwei Fu, Shuhua Yi, Lugui Qiu, Dehui Zou

Blood (2024) 144 (Supplement 1): 7228.

https://doi.org/10.1182/blood-2024-209328

Published: 2024

Journal Articles

A Phase Ib/II Study of Trovocabtagene Autoleucel (C-CAR088), an Anti-BCMA CAR T-Cell Therapy in Relapsed or Refractory Multiple Myeloma

Gang An, Yan Xu, Shuhua Yi, Rui Lyu, Jiaqi Huang, Wensi Li, Yiran Zhang, Liping Lan, Lugui Qiu

Blood (2024) 144 (Supplement 1): 7235.

https://doi.org/10.1182/blood-2024-194774

Published: 2024

Journal Articles

Performance and Challenges of the Lymphgen Classification Algorithm in Real-World Clinical Applications

Yujiao Jia, Haoxu Wang, Li Qin, Bingqing Huang, Qi Sun, Huijun Wang, Chengwen Li, Wei Liu, Yan Xu, Shuhua Yi, Lugui Qiu, Zhijian Xiao

Blood (2024) 144 (Supplement 1): 6233.

https://doi.org/10.1182/blood-2024-209761

Published: 2024

Journal Articles

Lenalidomide and Obinutuzumab in Patients with Relapsed/Refractory Waldenström Macroglobulinemia

Jingjing Yuan, Li Yuxi, Yuting Yan, Xiong Wenjie, Tengteng Yu, Tingyu Wang, Ying Yu, Lugui Qiu, Shuhua Yi

Blood (2024) 144 (Supplement 1): 6345.

https://doi.org/10.1182/blood-2024-206886

Published: 2024

Journal Articles

Isatuximab Plus Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Versus Vrd in Chinese Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant: IMROZ Subgroup Analysis

Gang An, Zhuogang Liu, Jie Jin, Zhen Cai, Wei Li, Zhongjun Xia, Xinan Cen, Yu Hu, Jian-Qing Mi, Hongmei Jing, Rong Zhan, Xiaoyan Qu, Xin Du, Dan Gao, Liang Zhao, Lugui Qiu

Blood (2024) 144 (Supplement 1): 7055.

https://doi.org/10.1182/blood-2024-199908

Published: 2024

Journal Articles

Evaluation of D-Vrd Induction/Consolidation Therapy with MRD-Adapted Maintenance in Transplant-Eligible NDMM Patients with Double-Hit Cytogenetic Abnormality (MMY2094)

Chenxing Du, Shuaishuai Zhang, Lugui Qiu, Gang An, Wenqiang Yan, Jian Cui, Weiwei Sui, Shuhui Deng, Yan Xu, Shuhua Yi, Dehui Zou

Blood (2024) 144 (Supplement 1): 7068.

https://doi.org/10.1182/blood-2024-207775

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Targeting Enterobacter cloacae attenuates osteolysis by reducing ammonium in multiple myeloma

Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE

A Phase I First-in-Human, Open-Label Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0500, a Humanized GPRC5D-BCMA-CD3 Trispecific Antibody, in Participants with Relapsed or Refractory Multiple Myeloma

MYD88 Mutations in Chronic Lymphocytic Leukemia Exhibit Distinct Biological Behaviors and Prognostic Implications

Spruce-TN CLL/SLL (cwCLL-002 study): An Ongoing Study of MRD-Guided Sonrotoclax Plus Zanubrutinib in Treatment-Naïve Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)

Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial

Single-Cell RNA Analysis of Bone Marrow Mononuclear Cells Reveals Abnormal Activation of T Cells and Monocytes, and Identifies CD35 As a Novel Biomarker and Therapeutic Target in Waldenstrom Macroglobulinemia

Dissecting the Interplay between Primary Central Nervous System Lymphoma Cells and the Microenvironment Using Single-Cell Transcriptomic Analysis

Acalabrutinib Versus Chlorambucil Plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia: A Randomized, Multicenter, Open-Label, Phase 3 Study

26S Proteasome Non-Atpase Subunit 3 (PSMD3/Rpn3) Is a Potential Therapeutic Target in Multiple Myeloma

Response-Driven Dose-Intensified Immunochemotherapy ± Autologous Stem Cell Transplantation in Previously Untreated Patients with High-Risk Aggressive B-Cell Lymphoma: Results of the DLCL002 Phase 2 Trial

TRIM28 Serves As a Key Regulator of Protein Homeostasis and Mediates Proteasome Inhibitor Resistance in Multiple Myeloma

EX103, a Newly Re-Designed CD20×CD3 Molecule, Induces High Response in Heavily Pretreated Relapsed/Refractory (R/R) Patients with B-Cell Non-Hodgkin Lymphoma (B-NHL)

Classification of NK-Large Granular Lymphocytic Leukemia By CD56 Expression

Promising Safety and Efficacy of Eque-Cel Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients: Primary Real World Data from a Single Center

A Phase Ib/II Study of Trovocabtagene Autoleucel (C-CAR088), an Anti-BCMA CAR T-Cell Therapy in Relapsed or Refractory Multiple Myeloma

Performance and Challenges of the Lymphgen Classification Algorithm in Real-World Clinical Applications

Lenalidomide and Obinutuzumab in Patients with Relapsed/Refractory Waldenström Macroglobulinemia

Isatuximab Plus Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Versus Vrd in Chinese Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant: IMROZ Subgroup Analysis

Evaluation of D-Vrd Induction/Consolidation Therapy with MRD-Adapted Maintenance in Transplant-Eligible NDMM Patients with Double-Hit Cytogenetic Abnormality (MMY2094)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only